Compare Flagstar Bank NA (FLG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Inovio Pharmaceuticals Inc — how do they compare? Flagstar Bank NA trades at $15.36 (market cap $6.26B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Flagstar Bank NA is far larger — about 65× Inovio Pharmaceuticals Inc's market cap, and Flagstar Bank NA pays a 0.27% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FLG | INO | |
|---|---|---|
Market Cap | $6.26B | $96.26M |
Sector | Financials | Health |
52-Week High | $15.28 | $2.87 |
52-Week Low | $10.72 | $1.05 |
Dividend Yield | 0.27% | — |
Enterprise Value | — | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $15.285, up 2.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $17.05. Recent earnings beat expectations in Q4 2025 and Q1 2026, though the company remains unprofitable on an annual basis with a net income margin of -2.71% in 2026. Positive developments include a proprietary technology transformation and a recent dividend declaration.
The outlook is cautiously optimistic, supported by analyst buy ratings and improving fundamentals, but risks include persistent negative profitability and high interest expenses. Upside is tied to continued execution on the turnaround and future earnings growth.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
